Location: United States
Freenome is working on a clinical study for early-stage detection of colorectal cancer. A blood test alternative to current screening methods will help encourage patients to get the regular recommended screening.
Many types of cancers are challenging to diagnose in the early stages as they have very few or no symptoms until the disease progresses. However, the chance of survival is much higher if the cancer is detected early.
To give cancer patients the best chance of recovery with treatment; advancements in early detection must be made. Freenome is one of the biotech startups working towards creating an accessible test a reality. In August 2020, they closed a $270 million series C financing round to advance their testing platform.
Freenome is developing a blood test for early-stage detection by using machine learning to identify biomarker patterns. Their platform analyses tumour and immune system signatures and looks for abnormalities compared to the biomarkers in healthy samples.
Currently, Freenome is working on a clinical study to develop a blood test that will detect early-stage colorectal cancer. This will provide a more patient-friendly test as opposed to current invasive screening tests that millions of people avoid.